Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
MacroGenics, Inc. MGNX
$6.61
-$0.25 (-3.78%)
На 18:00, 12 мая 2023
+152.19%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
424212796.00000000
-
week52high
7.90
-
week52low
2.13
-
Revenue
151941000
-
P/E TTM
-4
-
Beta
1.98027600
-
EPS
-2.06000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 20:00
Описание компании
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 09 авг 2022 г. |
| Barclays | Overweight | Overweight | 09 авг 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 12 июл 2022 г. |
| BMO Capital | Market Perform | Outperform | 12 июл 2022 г. |
| BMO Capital | Market Perform | Outperform | 11 июл 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 12 сент 2022 г. |
| Citigroup | Buy | Buy | 29 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 18 окт 2022 г. |
| BMO Capital | Outperform | Market Perform | 14 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 ноя 2022 г. |
| Guggenheim | Buy | Neutral | 23 ноя 2022 г. |
| Citigroup | Neutral | Buy | 23 ноя 2022 г. |
| Cowen & Co. | Market Perform | Outperform | 22 ноя 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 19 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| BIOTECH TARGET N V | A | 9079963 | 150000 | 19 янв 2023 г. |
| Chhabra Meenu | A | 36000 | 36000 | 03 янв 2023 г. |
| Liu Margaret | A | 36000 | 36000 | 03 янв 2023 г. |
| BIOTECH TARGET N V | A | 8929963 | 200000 | 27 дек 2022 г. |
| BIOTECH TARGET N V | A | 8729963 | 200000 | 23 дек 2022 г. |
| BIOTECH TARGET N V | A | 8529963 | 300000 | 22 ноя 2022 г. |
| Risser Eric Blasius | D | 0 | 8500 | 28 окт 2022 г. |
| Risser Eric Blasius | A | 53468 | 8500 | 28 окт 2022 г. |
| BIOTECH TARGET N V | A | 8229963 | 250000 | 24 окт 2022 г. |
| BIOTECH TARGET N V | A | 7979963 | 250000 | 21 окт 2022 г. |
Новостная лента
MacroGenics (MGNX) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment Research
09 мая 2023 г. в 19:07
MacroGenics (MGNX) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of $1.07. This compares to loss of $1.08 per share a year ago.
MacroGenics Announces Date of First Quarter 2023 Financial Results Conference Call
GlobeNewsWire
04 мая 2023 г. в 16:30
ROCKVILLE, MD, May 04, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2023 after the market closes on Tuesday, May 9, 2023. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, May 9, 2023, at 4:30 pm ET.
MacroGenics to Participate in Upcoming Investor Conferences
GlobeNewsWire
24 апр 2023 г. в 18:15
ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences:
Why MacroGenics Stock Inched Higher on Monday
The Motley Fool
20 мар 2023 г. в 18:59
Two analysts raised their price targets on the cancer-focused biotech. They are the latest prognosticators to adjust their takes on the company following its latest earnings release.
Why MacroGenics Stock Tumbled Today
The Motley Fool
17 мар 2023 г. в 18:15
An analyst downgraded his recommendation on the cancer-focused biotech. It seemed post-earnings profit-taking also played a role in the selloff.